# DeepSeek for Pharma & Biotech: Uses, Risks & Controls

- **URL**: https://chat-deep.ai/solutions/deepseek-for-pharma-biotech/
- **Published**: 2026-06-13T12:13:12+00:00
- **Modified**: 2026-07-29T12:14:46+00:00
- **Category**: DeepSeek Solutions
- **Word count**: 3698
- **Code blocks**: 0
- **Description**: Explore DeepSeek for pharma and biotech workflows while addressing scientific accuracy, sensitive data, validation, governance and expert-review requirements.

## H1


## H2 目录
- Table of Contents
- What Is DeepSeek, and Why Are Pharma and Biotech Teams Paying Attention?
- Why This Matters in Pharma and Biotech
- DeepSeek Use Cases Across Pharma and Biotech Teams
- Where DeepSeek Is a Good Fit—and Where It Is Not
- DeepSeek for Pharma and Biotech Teams: Good-Fit Workflows
- Poor-Fit or High-Risk Workflows Without Validation
- Deployment Options for Regulated Teams
- Data Privacy, IP, and Security Considerations
- Regulatory and Quality Considerations
- A Practical 30/60/90-Day Pilot Plan
- KPI and ROI Framework
- DeepSeek vs Other LLM Options for Pharma and Biotech
- Best Practices for Pharma and Biotech Teams
- Common Mistakes to Avoid
- Conclusion
- FAQ

## 正文
Last updated: July 29, 2026

DeepSeek for Pharma and Biotech Teams can be useful for knowledge work, literature review, document drafting, data extraction, coding, and reasoning-heavy workflows. But in pharma and biotech, usefulness is not enough. Any use of DeepSeek in regulated or sensitive workflows requires validation, privacy review, human oversight, and a clear AI governance model.

This article is a practical evaluation guide for life-sciences teams. It is not medical, legal, regulatory, or clinical advice. DeepSeek should not be treated as a validated scientific authority, a clinical decision-maker, or a substitute for qualified experts.

The timing matters. FDA recognizes that AI is increasingly used across the drug product lifecycle, including nonclinical, clinical, postmarketing, and manufacturing phases. EMA and FDA have also published good AI practice principles for drug development, emphasizing human-centric design, a risk-based approach, clear context of use, data governance and documentation, risk-based performance assessment, life-cycle management, and clear information for users.


### Table of Contents


### What Is DeepSeek, and Why Are Pharma and Biotech Teams Paying Attention?

DeepSeek is a family of large language and reasoning models that can be accessed in different ways: through public-facing chat services, through the DeepSeek API, or through open/self-hosted model releases such as DeepSeek R1.

API status verified July 29, 2026: DeepSeek’s documented API models are deepseek-v4-flash and deepseek-v4-pro. The current documentation lists thinking and non-thinking modes, JSON Output, tool calls, and a one-million-token context window. DeepSeek’s April 2026 announcement established July 24, 2026 at 15:59 UTC as the cutoff for deepseek-chat and deepseek-reasoner. The deadline has passed, and those identifiers are not present in the current official model list. Pharma and biotech teams should migrate through formal change control and revalidate regulated, GxP-relevant, safety-related, or scientifically consequential workflows before production use.

DeepSeek R1 is especially relevant to technical teams because its GitHub repository states that the code repository and model weights are licensed under the MIT License and support commercial use, modifications, derivative works, and distillation, subject to the specific notes for distilled models.


> Important caveat: Model names, pricing, API features, context lengths, license terms, and deployment options can change quickly. Before implementing DeepSeek in any pharma or biotech workflow, teams should verify the latest official DeepSeek documentation, legal terms, model license, and privacy policy.

There is also an important distinction between using a public chat interface and building a controlled enterprise system. The public app may be useful for personal learning or non-sensitive experimentation. The API may be suitable for controlled prototypes. Depending on vendor availability, enterprise contracts, and internal infrastructure, a controlled private deployment pattern—such as a private cloud environment, VPC-based architecture, self-hosted open-weight model, or a retrieval-augmented generation system over approved documents—may be more appropriate for sensitive IP, clinical, regulatory, or GxP-adjacent workflows.


### Why This Matters in Pharma and Biotech

Pharma and biotech teams operate in an unusually demanding information environment. They work with scientific literature, clinical protocols, investigator brochures, study reports, SOPs, regulatory dossiers, safety narratives, manufacturing records, medical information responses, and highly specialized internal knowledge.

The opportunity is not simply “AI-generated text.” The deeper opportunity is reducing friction in expert workflows: helping teams find evidence faster, compare documents, extract structured data, draft non-final content, summarize controlled corpora, generate code, and triage information for review.

At the same time, life-sciences teams face constraints that many generic AI deployments do not:

- Sensitive intellectual property, including targets, assays, compounds, sequences, formulations, and regulatory strategy.

- Patient-related information, including PHI, PII, safety reports, and trial data.

- GxP, quality, auditability, and documentation expectations.

- Scientific uncertainty, where a fluent answer can still be wrong.

- Regulatory impact, where an AI output may influence evidence, safety, quality, or benefit-risk decisions.

NIST’s AI Risk Management Framework describes trustworthy AI characteristics such as validity and reliability, safety, security and resilience, accountability and transparency, explainability and interpretability, privacy enhancement, and bias management. For pharma and biotech teams, those are not abstract principles. They translate into concrete requirements: context-of-use definition, risk classification, validation evidence, audit logs, human review, access controls, and change management.


> Risk note: A model that is useful for drafting a literature summary is not automatically acceptable for generating evidence for a regulatory submission, triaging adverse event cases, or influencing clinical decisions.


### DeepSeek Use Cases Across Pharma and Biotech Teams

The best initial use cases for DeepSeek for pharma teams and DeepSeek for biotech teams are usually low- to medium-risk knowledge workflows where outputs are reviewed by qualified humans. Higher-risk workflows may still be explored, but only with formal validation, controlled data, traceability, and documented oversight.


Team | Workflow | How DeepSeek May Help | Risk Level | Required Controls
Discovery biology | Target research | Summarize literature, compare pathways, draft hypothesis maps | Medium | Source citations, expert review, controlled corpus
Medicinal chemistry | Hypothesis generation | Assist with SAR discussion drafts, patent landscape summaries, idea generation | Medium–High | No autonomous design decisions, IP controls, chemist review
Scientific intelligence | Literature review | Screen abstracts, summarize papers, extract study attributes | Medium | RAG, citation verification, reviewer sampling
Bioinformatics | Coding assistance | Generate Python/R scripts, debug pipelines, explain code | Medium | Code review, test datasets, version control
Clinical operations | Protocol review | Identify inconsistencies, draft query lists, summarize inclusion/exclusion criteria | High | Clinical expert review, audit trail, no final decisions
Clinical strategy | Trial feasibility | Summarize site intelligence, epidemiology, and precedent information | Medium–High | Approved data sources, documentation, human sign-off
Medical writing | CSR or protocol drafts | Draft non-final sections, summarize tables, create first-pass outlines | High | Medical writer review, QC, source traceability
Regulatory affairs | Regulatory intelligence | Summarize public guidance, compare agency precedents, draft briefing outlines | High | Regulatory review, official sources only, version control
Pharmacovigilance | AE triage support | Extract entities, summarize narratives, prioritize cases for review | High | Validated workflow, safety expert review, audit logs
Medical information | Response drafting | Draft evidence-based response templates from approved materials | High | Approved content library, medical/legal/regulatory review
Manufacturing / QA / QC | SOP search | Retrieve SOP sections, summarize deviations, draft CAPA outlines | High | GxP validation, access control, electronic record controls
Competitive intelligence | Market and trial tracking | Summarize public trial registries, publications, press releases | Medium | Public sources, analyst review
Medical affairs / commercial | Content review | Identify unsupported claims or missing references in draft materials | High | MLR workflow integration, approved claims library

EMA’s reflection paper recognizes potential AI/ML use across the medicinal product lifecycle and highlights pharmacovigilance-related applications such as adverse event report management and signal detection, while also emphasizing existing good pharmacovigilance practice requirements.


### Where DeepSeek Is a Good Fit—and Where It Is Not


### DeepSeek for Pharma and Biotech Teams: Good-Fit Workflows

DeepSeek may be a good fit when the task is knowledge-heavy, repetitive, document-based, and subject to human review. Examples include:

- Internal knowledge search over approved documents.

- Literature summarization with linked sources.

- Drafting non-final scientific, medical, or regulatory content.

- Extracting structured information from controlled corpora.

- Generating and explaining code for analytics workflows.

- Creating study comparison tables.

- Drafting review checklists for experts.

- Triage workflows where the model prioritizes items for human review rather than making final decisions.

RAG is especially useful in life sciences because it can ground answers in approved documents rather than relying only on model memory. A 2025 PLOS Digital Health systematic review explains that retrieval-augmented generation grounds LLM responses by exposing them to external knowledge sources, helping address limitations such as outdated training data, hallucinations, and limited transparency. A separate healthcare RAG review reports that RAG can improve factual consistency and reduce hallucinations, while noting that healthcare deployment remains fragmented and requires careful evaluation.


> Practical tip: For most pharma and biotech teams, the first production-grade DeepSeek workflow should not be “ask the model anything.” It should be a narrow, retrieval-based assistant connected to approved documents, with citations, logging, role-based access, and documented human review.


### Poor-Fit or High-Risk Workflows Without Validation

DeepSeek should not be used without validation and oversight for:

- Autonomous clinical decisions.

- Direct patient advice.

- Final regulatory submissions without expert review.

- Automated adverse event seriousness, causality, or expectedness decisions.

- Unverified scientific claims.

- Uploading confidential patient data, trade secrets, or unpublished compound information into public tools.

- Automated quality decisions in GxP systems without validation.

- Any workflow where an incorrect output could affect patient safety, product quality, or regulatory conclusions.

DeepSeek’s own privacy policy warns that model outputs may not be factually accurate and says users should not rely on the factual accuracy of outputs from its models. Clinical AI literature also shows that LLM-generated summaries may contain hallucinations and omissions, and that evaluation should consider clinical impact rather than surface fluency alone.


### Deployment Options for Regulated Teams

The deployment model is often more important than the model choice. A public chat tool, API integration, private deployment, and RAG system create very different risk profiles.


Deployment option | Suitable for | Advantages | Risks | Recommended controls
Public DeepSeek app | Non-sensitive learning, public information exploration | Fast, low setup | Data privacy, retention, user input exposure, no enterprise control | Ban sensitive data, user policy, training
DeepSeek API | Controlled prototypes, developer workflows | API integration, structured output, tool calls | Vendor risk, data processing, logging, cross-border concerns | DPA/legal review, redaction, access control
Private cloud / VPC deployment | Sensitive internal workflows | Better network and access control | Cost, integration, validation burden | Security architecture, logging, monitoring
Self-hosted open-weight model | IP-sensitive teams, advanced ML groups | More control, customization potential | Infrastructure, model governance, license review | Model registry, validation, patching, security testing
RAG over approved documents | Knowledge search, medical info, regulatory intelligence | Better traceability and citation support | Retrieval errors, stale documents, permissions leakage | Document governance, source ranking, citation checks
Agentic workflow with tools | Structured tasks, database queries, workflow automation | Can connect to systems and enforce steps | Tool misuse, cascading errors, audit complexity | Tool allowlists, human approval gates, sandboxing
Hybrid model strategy | Enterprise AI platform | Match model to use case | Complexity, inconsistent controls | Central AI governance and model evaluation framework

DeepSeek’s API documentation describes structured JSON output and tool-calling capabilities. The tool-calling documentation also clarifies that the model does not execute functions itself; the user-provided system executes the function and returns results to the model. This distinction matters for regulated teams because tool execution, data access, approvals, and audit trails must be designed outside the model.


> Compliance note: Avoid using public chat tools for confidential pharma or biotech data unless legal, privacy, security, quality, and compliance teams have explicitly approved that use.


### Data Privacy, IP, and Security Considerations

Data privacy is one of the highest-priority issues when evaluating DeepSeek in life sciences.

DeepSeek’s privacy policy states that user input may include text input, voice input, prompts, uploaded files, photos, feedback, chat history, and other content provided to its model and services. It also says the services are not designed or intended to process sensitive personal data, including health, genetic, biometric, children’s data, and other sensitive categories.

These statements apply to DeepSeek services governed by the referenced privacy policy. Self-hosted deployments, enterprise agreements, private infrastructure arrangements, and downstream applications may involve different data-handling responsibilities and should be reviewed separately. These points are especially important for teams handling PHI, PII, clinical trial data, unpublished research, regulatory strategy, compound structures, assay data, or manufacturing records.

Privacy concerns are not theoretical. AP reported that Italy’s data protection authority blocked access to the DeepSeek application and opened an investigation after raising questions about what personal data is collected, where it is stored, and how users are notified. Reuters also reported that some U.S. Commerce Department bureaus prohibited DeepSeek on government-furnished equipment because of security and sensitive-information concerns.

Before using DeepSeek with sensitive data, confirm:

- What data is sent to the model.

- Whether prompts, files, outputs, metadata, and logs are retained.

- Where data is processed and stored.

- Whether data is used for training or model improvement.

- Whether opt-out rights or enterprise contractual controls apply.

- How data can be deleted.

- Whether audit logs are available.

- Whether the vendor meets internal security requirements.

- Whether the workflow is GxP-relevant.

- Whether PHI, PII, patient narratives, sequences, compounds, or trade secrets are involved.

- Whether human review is documented.

For many pharma and biotech organizations, private deployment or RAG over approved internal documents will be safer than uncontrolled public chat use.


### Regulatory and Quality Considerations

The regulatory question is not “Can DeepSeek produce a useful answer?” It is “Can the team demonstrate that the AI system is fit for its intended context of use, sufficiently controlled, and appropriately reviewed?”

FDA’s January 2025 draft guidance on AI for drug and biological product regulatory decision-making is a Draft Level 1 Guidance that is not for implementation and contains non-binding recommendations. It describes a risk-based credibility assessment framework for AI models used to produce information or data intended to support regulatory decision-making about safety, effectiveness, or quality. FDA also states that AI submissions to CDER have increased and span nonclinical, clinical, postmarketing, and manufacturing phases.

EMA’s AI reflection paper emphasizes human agency and oversight, technical robustness and safety, privacy and data governance, transparency, accountability, diversity, non-discrimination, and fairness. It also warns that very large, non-transparent AI models introduce risks that need mitigation during development and deployment, including bias and risks to patient safety and clinical study integrity.

For GxP-relevant systems, teams should also consider electronic records and signatures. 21 CFR Part 11 applies to certain electronic records that are created, modified, maintained, archived, retrieved, or transmitted under FDA records requirements, and computer systems, controls, and documentation maintained under Part 11 must be available for FDA inspection. FDA’s Part 11 guidance describes the agency’s current thinking and notes that Part 11 remains in effect, even where FDA exercises enforcement discretion for certain requirements.


> Compliance note: This article is not legal or regulatory advice. Consult regulatory, quality, legal, privacy, security, clinical, and pharmacovigilance leaders before using DeepSeek in regulated workflows.

Key controls include:

- Defined context of use.

- Risk classification.

- Validation plan and acceptance criteria.

- Gold-standard test sets.

- Human-in-the-loop review.

- Audit trails and prompt/output logging.

- Version control for model, prompts, retrieval corpus, and tools.

- Change control and revalidation triggers.

- Access controls and least-privilege permissions.

- Periodic monitoring for drift, hallucination, retrieval failure, and user misuse.


### A Practical 30/60/90-Day Pilot Plan


Timeline | Objective | Actions | Deliverables | Success metrics
30 days | Select and de-risk pilot | Choose low-risk workflows, define data boundaries, run legal/security/privacy review, compare DeepSeek with baseline tools, define human review | Use-case charter, risk assessment, data policy, evaluation plan | Approved pilot, no sensitive-data leakage, baseline established
60 days | Build controlled prototype | Add RAG over approved documents, test prompts, evaluate accuracy, citations, hallucination rate, latency, cost, and reviewer burden | Working prototype, test report, reviewer feedback | Citation accuracy, lower review time, acceptable error profile
90 days | Run limited production pilot | Add monitoring, role-based access, SOPs, audit logs, escalation rules, and change control | Pilot SOP, monitoring dashboard, go/no-go decision | Adoption, expert time saved, compliance readiness, defect rate

The FDA/EMA good AI practice principles emphasize context of use, multidisciplinary expertise, data governance, risk-based performance assessment, and life-cycle management. A 30/60/90-day pilot should be designed around those principles, not around a demo alone.


### KPI and ROI Framework

Measure DeepSeek by workflow quality, not just model cost. Useful KPIs include:


KPI | Why it matters
Expert hours saved | Shows whether the tool reduces burden on high-cost specialists
Literature review turnaround time | Measures speed in evidence-heavy workflows
Draft cycle time | Useful for medical writing, regulatory, and SOP workflows
Citation accuracy | Critical for scientific and regulatory trust
Hallucination rate | Measures unsupported or incorrect outputs
Reviewer correction burden | Shows whether the model creates hidden work
Safety triage agreement | Relevant for pharmacovigilance pilots
Cost per completed workflow | Better than cost per token alone
Time to answer | Important for medical information and knowledge search
User adoption | Shows whether experts trust the tool
Compliance deviations | Tracks governance failures
Audit readiness | Measures traceability and inspection preparedness

A model that is cheap per token may still be expensive if reviewers spend more time correcting errors. Conversely, a model that requires more infrastructure may be worthwhile if it reduces high-value expert bottlenecks and produces traceable outputs.


### DeepSeek vs Other LLM Options for Pharma and Biotech

DeepSeek may be attractive for cost-sensitive experimentation, reasoning workflows, developer tasks, structured outputs, long-context use cases, and open/self-hosted evaluation. Its API documentation currently supports JSON output and tool calls, and R1’s official repository describes permissive use for the R1 series.

However, other LLM options may be preferred when the priority is enterprise governance, healthcare-specific safeguards, contractual privacy commitments, regional data residency, mature admin controls, vendor support, or a broader compliance ecosystem.

The right choice depends on:

- Use case risk.

- Data sensitivity.

- Need for private deployment.

- Model validation burden.

- Retrieval quality.

- Auditability.

- Security architecture.

- Vendor review.

- Total cost of ownership.

- Availability of internal AI/ML and compliance expertise.

A practical approach is to maintain a model evaluation matrix rather than choosing a single model for every workflow. For example, one model may be used for public literature summaries, another for internal document RAG, another for coding support, and a different validated system for GxP-relevant workflows.


### Best Practices for Pharma and Biotech Teams

Use this checklist before scaling DeepSeek:

- Start with low-risk workflows.

- Use approved data only.

- Prefer retrieval-based answers with citations.

- Require expert review before use.

- Define context of use.

- Validate against gold-standard datasets.

- Log prompts, outputs, sources, model versions, and reviewer decisions where appropriate.

- Separate experimentation from GxP production.

- Use role-based access controls.

- Monitor hallucinations, omissions, drift, and retrieval failures.

- Document model, prompt, corpus, and tool changes.

- Train users on what not to enter.

- Review privacy, IP, cybersecurity, and data residency.

- Add escalation rules for uncertain or high-impact outputs.

- Reassess the system when models, prompts, data, or workflows change.

NIST frames AI risk management around governance, mapping, measuring, and managing risk across the AI lifecycle. That structure is a useful starting point for AI governance in life sciences.


### Common Mistakes to Avoid

The most common failure mode is treating DeepSeek as a generic productivity tool rather than a controlled AI system.

Avoid these mistakes:

- Treating DeepSeek as a validated scientific authority.

- Uploading confidential data to public tools.

- Using AI-generated text in regulatory documents without expert review.

- Ignoring privacy and data residency.

- Measuring only token cost instead of reviewer burden.

- Skipping legal, security, privacy, and quality review.

- Failing to define context of use.

- Allowing uncontrolled prompt changes in validated workflows.

- Connecting agentic tools to live systems without approval gates.

- Assuming open-source or open-weight availability means risk-free.

- Using outdated or unapproved internal documents in RAG.

- Failing to monitor model changes and output drift.


> Risk note: The most dangerous DeepSeek output is not obviously wrong. It is fluent, plausible, uncited, and slightly incorrect in a way that only an expert would notice.


### Conclusion

DeepSeek can be a valuable option for pharma and biotech teams when it is used as part of a governed, validated, human-reviewed AI workflow. It may support literature review, internal knowledge search, document drafting, data extraction, coding, regulatory intelligence, medical information, pharmacovigilance triage, and other expert workflows.

The safest path is to start with low-risk knowledge and document workflows, use approved data, add retrieval and citations, measure performance, and scale only after privacy, security, quality, and regulatory controls are in place.

For regulated teams, the question is not whether DeepSeek can generate useful content. The real question is whether the organization can prove that the full system—model, data, prompts, tools, humans, controls, and records—is appropriate for its intended use.


### FAQ


#### What is DeepSeek for pharma and biotech teams?

DeepSeek for Pharma and Biotech Teams refers to the use of DeepSeek models or APIs to support life-sciences workflows such as literature review, internal knowledge search, document drafting, data extraction, coding, regulatory intelligence, and safety triage. It should be implemented with privacy controls, validation, and human review.


#### Can pharma companies use DeepSeek safely?

They may be able to use DeepSeek safely for selected workflows, but only after privacy, security, legal, quality, and regulatory review. Public chat use should generally be restricted to non-sensitive information unless explicitly approved. DeepSeek’s privacy policy states that user inputs may include prompts, uploaded files, and chat history, and that personal data may be stored and processed in China.


#### Is DeepSeek suitable for drug discovery?

DeepSeek may support knowledge tasks in drug discovery, such as summarizing literature, comparing mechanisms, drafting hypotheses, or assisting with code. It should not be treated as a validated drug discovery engine or used to make autonomous scientific decisions without expert review and fit-for-purpose evaluation.


#### Can DeepSeek be used for clinical trial documents?

DeepSeek may assist with non-final drafts, protocol comparisons, eligibility criteria summaries, and document review checklists. Clinical trial documents require expert review, traceability, and quality controls, especially where outputs may influence study conduct or regulatory submissions.


#### Can DeepSeek support pharmacovigilance?

DeepSeek may be evaluated for support tasks such as narrative summarization, entity extraction, prioritization, and quality checks. It should not autonomously determine seriousness, causality, expectedness, or reporting obligations without a validated process and qualified safety review. EMA recognizes potential AI support for pharmacovigilance activities while emphasizing applicable good pharmacovigilance practice requirements.


#### Should teams use the DeepSeek public app or private deployment?

For sensitive pharma and biotech workflows, private deployment, controlled API use, or RAG over approved documents is usually safer than public chat. The public app may be limited to non-sensitive exploration. Any use involving PHI, PII, trade secrets, clinical data, unpublished research, or regulatory strategy requires formal review.


#### What are the biggest risks of DeepSeek in biotech?

The main risks include data privacy, IP exposure, hallucinations, unsupported scientific claims, lack of validation, poor auditability, model changes, prompt leakage, biased outputs, and misuse in high-stakes workflows.


#### How should regulated teams validate AI outputs?

Teams should define context of use, classify risk, create test datasets, measure accuracy and hallucination rates, document reviewer corrections, validate retrieval quality, monitor drift, control model and prompt versions, and maintain audit trails. FDA’s AI guidance emphasizes a risk-based credibility assessment for AI used to support regulatory decision-making.


#### Is DeepSeek better than other LLMs for pharma?

There is no universal “best” model for pharma. DeepSeek may be attractive for certain reasoning, cost, developer, and open/self-hosted workflows. Other models may be better for enterprise governance, contractual controls, vendor support, data residency, or compliance tooling. The right model depends on use case, data sensitivity, validation burden, and total cost of ownership.


#### What is the best first pilot use case?

The best first pilot is usually a low-risk internal knowledge or literature workflow: for example, a RAG assistant that answers questions from approved SOPs, public guidance, publications, or internal non-GxP documents with citations and expert review.

## 内部链接
- [DeepSeek](https://chat-deep.ai/)

## 外部链接
- [AI is increasingly used across the drug product lifecycle](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development)
- [DeepSeek API](https://api-docs.deepseek.com/)
- [DeepSeek R1](https://github.com/deepseek-ai/DeepSeek-R1)
- [MIT License](https://github.com/deepseek-ai/DeepSeek-R1/blob/main/LICENSE)
- [NIST’s AI Risk Management Framework](https://www.nist.gov/itl/ai-risk-management-framework)
- [medicinal product lifecycle](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf)
- [DeepSeek’s API documentation](https://api-docs.deepseek.com/quick_start/pricing)
- [tool-calling capabilities](https://api-docs.deepseek.com/guides/tool_calls)
- [DeepSeek’s privacy policy](https://cdn.deepseek.com/policies/en-US/deepseek-privacy-policy.html)
- [Italy’s data protection authority blocked access](https://apnews.com/article/dc7e87835ed7a125b5e46614ddbd80d0)
- [Commerce Department bureaus prohibited DeepSeek](https://www.reuters.com/technology/artificial-intelligence/us-commerce-department-bureaus-ban-chinas-deepseek-government-devices-sources-2025-03-17/)
- [EMA’s AI reflection paper](https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle-scientific-guideline)
- [21 CFR Part 11](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11)
- [FDA’s Part 11 guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application)
- [good AI practice principles](https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development)
- [(no anchor)](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fchat-deep.ai%2Fsolutions%2Fdeepseek-for-pharma-biotech%2F)
- [(no anchor)](https://twitter.com/intent/tweet?url=https%3A%2F%2Fchat-deep.ai%2Fsolutions%2Fdeepseek-for-pharma-biotech%2F&text=DeepSeek%20for%20Pharma%20and%20Biotech%20Teams%3A%20Use%20Cases%2C%20Risks%2C%20and%20Implementation%20Guide)
- [(no anchor)](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fchat-deep.ai%2Fsolutions%2Fdeepseek-for-pharma-biotech%2F&title=DeepSeek%20for%20Pharma%20and%20Biotech%20Teams%3A%20Use%20Cases%2C%20Risks%2C%20and%20Implementation%20Guide)